We picked Adamas Pharmaceuticals (ADMS) stock in our portfolio last year (see initiation article with full details).

We are reiterating Buy on Adamas stock ahead of PDUFA.

ADS amantadine CEO drug levodopa lid PD release stock treatment


There are several risks to the buy thesis, with an estimated 50% downside in the event of unexpected SAEs or other clinical setbacks.

The graphic below is an excellent illustration for helping investors understand how PD patients' responses to L-DOPA evolve over time, from longer, predictable periods of "On-Time" and less frequent administrations to more frequent doses with a higher degree of variability.

administration couple disease DOPA events levodopa Parkinson patient Sanofi treatment